Clostridioides difficile infection (CDI) remains a significant challenge in nosocomial settings due to the bacterium’s evolving nature and its impact on clinical management. Recent advancements have introduced promising therapeutic strategies, including monoclonal antibodies and live biotherapeutic products, which require careful application to maximize their benefits. Future innovations under investigation, such as bacteriophages, vaccines, and antibiotic inhibitors, offer additional hope for managing CDI. Prevention and surveillance strategies remain critical in curbing the spread of infection and mitigating its impact on healthcare systems.
This review provides a comprehensive examination of CDI, covering key epidemiological trends, risk factors, clinical manifestations, and diagnostic tools. It also explores both current and emerging options for prevention and treatment. The review further highlights the importance of integrating innovative therapies with robust infection control measures to address this persistent healthcare challenge.
Reference: Di Bella S, Sanson G, Monticelli J, et al. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29. PMID: 38421181; PMCID: PMC11324037.
